ThinkCyte
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Japan · 51-200 Employees
View Company Info for Free
Overview
Headquarters
7-3-1 Hongo, Hongo, Tokyo, 113-0033, Jap...Website
www.thinkcyte.comRevenue
$43.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About ThinkCyte
ThinkCyte, headquartered in Tokyo, Japan, is a biotechnology company which develops innovative life science research, diagnostics, and treatments using integrated multidisciplinary technologies, and was founded in 2016. ThinkCyte’s mission is to provide scientists and biomedical professionals with a transformational single-cell technology that accelerates biological discoveries and enables the development of novel treatments and diagnostics through the integration of advanced hardware, machine learning, and biotechnology.Explore more
ThinkCyte Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ThinkCyte your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if ThinkCyte has recently received funding, and reach out quickly before it becomes old news!
ThinkCyte, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if ThinkCyte had a recent Job posting/layoffs
Earning: See what the market has to say on ThinkCyte recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at ThinkCyte
Check out if ThinkCyte is spiking on competitors!
Product Launch: Get notified when ThinkCyte launches new products
Funding: Get notified immidiatlly once ThinkCyte has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at ThinkCyte
Find 2 more new buyers
Company Profile Activity
Activity Insights
ThinkCyte is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ThinkCyte is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ThinkCyte.
ThinkCyte financials insights
Gather financial insights about ThinkCyte, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$15.3M
2021
Series B
$26M
2023
Private Equity
$24M
2024
Series C
$32M
ThinkCyte Tech Stack
A closer look at the technologies used by ThinkCyte
See more technologies
Most Recent Scoops
Hiring Plans
ThinkCyte is hiring in Sales for the first time in 12 months.
Hiring Plans
Hiring Plans
ThinkCyte has more open roles in Marketing than it has had at any time in the past 12 months.
Hiring Plans
Funding
Funding
Hiring Plans
ThinkCyte has more open roles in Engineering & Technical than it has had at any time in the past 12 months.
Hiring Plans
ThinkCyte News & Media
ThinkCyte expands product portfolio to drive innovation in drug discovery and disease research.
TOKYO, Jan. 28, 2025 /PRNewswire/ -- ThinkCyte, a biotechnology company pioneering novel artificial intelligence (AI)-based cell analysis and sorting instruments, announced today that it will begin the pre-commercial launch of its new cell analysis platform, VisionCyte™. The announcement coincides with the 2025 Society for Laboratory Automation and Screening (SLAS) conference in San Diego, CA from January 27-30, 2025, where VisionCyte was named a finalist for the 2025 New Product Award. The launThinkCyte Secures $32 million in Series C Funding to Drive Global Expansion of VisionSort™
TOKYO and REDWOOD CITY, Calif., Aug. 31, 2024 /PRNewswire/ -- ThinkCyte today announced the successful completion of its Series C funding round. Including the equity financing secured last November, the company raised an additional $15 million in the extension round, bringing the total to $32 million. The extension round was led by Japan Green Investment Corp. for Carbon Neutrality (JICN), KIRIN-GB Fund I L.P., and SMBC Venture Capital No. 7 Investment Limited Partnership. The companyThinkCyte Launches New Website and Showcases VisionSortTM at Global Events
TOKYO, May 6, 2024 /PRNewswire/ -- ThinkCyte today announced that it will be presenting at three major international scientific conferences in the first week of May and the launch of its updated website. The company will have a presence at the American Society for Immunology (AAI) from...ThinkCyte advances biopharma phenotypic drug discovery programs with publication and presentation milestones
TOKYO, April 1, 2024 /PRNewswire/ -- ThinkCyte today announced the publication of a paper in the March issue of Cell Reports Methods on a new method for high-throughput drug discovery. Together with a joint research group including investigators at the University of Tokyo and the University of British Columbia, the team describes the development of an approach to identify new candidate drugs by CRISPR screening using Ghost Cytometry; its artificial intelligence (AI)-driven, label-free, morpholog
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ThinkCyte
Sign Up For FreeTo access detailed company insights
ThinkCyte, headquartered in Tokyo, Japan, is a biotechnology company which develops innovative life science research, diagnostics, and treatments using integrated multidisciplinary technologies, and was founded in 2016. ThinkCyte’s mission is to provide scientists and biomedical professionals with a transformational single-cell technology that acce... Read More
